[Reperfusion syndrome during thrombolytic therapy of myocardial infarct].
Infarct-related coronary artery occlusion was found in 90 out of 97 patients with myocardial infarction and intracoronary thrombolytic therapy was performed by using streptokinase. Electrocardiographic, clinical, and hemodynamic manifestations of the reperfusion syndrome were assessed when the coronary artery became patent. It was concluded that arrhythmic manifestations of the syndrome were the most life-threatening as they might lead to fatal arrhythmias. It was demonstrated that prognostically unfavorable reperfusion-induced arrhythmias might be abolished by a preventive administration of mexitil and, to a lesser degree, isoptin. Good mexitil tolerance and certain limitations of isoptin therapy were also underlined.
Golikov
A P
AP
Rudnev
D V
DV
D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000627:therapeutic use; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D011379:Prognosis; D013300:Streptokinase / Q000627:therapeutic use; D013577:Syndrome; D014700:Verapamil / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D008801:Mexiletine; D014700:Verapamil; D013300:Streptokinase
Reperfuzionnyĭ sindrom pri tromboliticheskoĭ terapii infarkta miokarda.